LENZ Therapeutics and Graphite Bio Announce Merger Agreement
SAN DIEGO & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of n